Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-02-24 11:11:14 UTC |
---|
Update Date | 2023-02-21 17:15:54 UTC |
---|
HMDB ID | HMDB0001877 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Valproic acid |
---|
Description | Valproic acid (VPA) is considered to be a drug of first choice and one of the most frequently-prescribed antiepileptic drugs worldwide for the therapy of generalized and focal epilepsies, including special epileptic. It is a broad-spectrum antiepileptic drug and is usually well tolerated. Rarely, serious complications may occur in some patients, including hemorrhagic pancreatitis, coagulopathies, bone marrow suppression, VPA-induced hepatotoxicity and encephalopathy, but there is still a lack of knowledge about the incidence and occurrence of these special side effects. VPA has been approved for stabilization of manic episodes in patients with bipolar disorder. It is also used to treat migraine headaches and schizophrenia. As the use of VPA increases, the number of both accidental and intentional exposures increases. This is paralleled by more reports of VPA-induced toxicity. VPA is relatively contraindicated in pregnancy due to its teratogenicity. It is a known folate antagonist, which can cause neural tube defects. Thus, folic acid supplements may alleviate teratogenic problems. Women who become pregnant whilst taking valproate should be counselled as to its risks. VPA is an inhibitor of the enzyme histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. Patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a median 75% reduction in latent HIV infection. VPA is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain. Valproic Acid dissociates to the valproate ion in the gastrointestinal tract. (PMID: 18201150 , 17496767 ). |
---|
Structure | InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10) |
---|
Synonyms | Value | Source |
---|
2-N-Propyl-N-valeric acid | ChEBI | 2-PROPYL-pentanoIC ACID | ChEBI | 2-Propylpentanoic acid | ChEBI | 2-Propylvaleric acid | ChEBI | 4-Heptanecarboxylic acid | ChEBI | Acide valproique | ChEBI | Acido valproico | ChEBI | Acidum valproicum | ChEBI | Depakene | ChEBI | Di-N-propylacetic acid | ChEBI | Di-N-propylessigsaeure | ChEBI | Dipropylacetic acid | ChEBI | DPA | ChEBI | N-DPA | ChEBI | Valproinsaeure | ChEBI | VPA | ChEBI | 2-N-Propyl-N-valerate | Generator | 2-PROPYL-pentanoate | Generator | 2-Propylpentanoate | Generator | 2-Propylvalerate | Generator | 4-Heptanecarboxylate | Generator | Di-N-propylacetate | Generator | Dipropylacetate | Generator | Valproate | Generator | (N-C3H7)2chcooh | HMDB | (S)-2-Propyl-4-pentanoate | HMDB | (S)-2-Propyl-4-pentanoic acid | HMDB | Alti-valproic | HMDB | Apo-divalproex | HMDB | Apo-valproic | HMDB | Apo-valproic syrup | HMDB | Avugane | HMDB | Baceca | HMDB | Convulex | HMDB | Delepsine | HMDB | Depakin | HMDB | Depakin chrono | HMDB | Depakine | HMDB | Depakine chrono | HMDB | Deproic | HMDB | Di-N-propylessigsaure | HMDB | Divalproex | HMDB | DOM-divalproex | HMDB | Dom-valproate | HMDB | DOM-valproic | HMDB | Dom-valproic acid | HMDB | DOM-valproic acid e.c. | HMDB | Dom-valproic acid syrup | HMDB | Epiject i.v. | HMDB | Epilex | HMDB | Epilim | HMDB | Epival | HMDB | Epival er | HMDB | Ergenyl | HMDB | Gen-divalproex | HMDB | Kyselina 2-propylvalerova | HMDB | Med valproic | HMDB | Mylproin | HMDB | Myproate | HMDB | Myproic acid | HMDB | N-Dipropylacetic acid | HMDB | Novo-divalproex | HMDB | Novo-valproic | HMDB | Novo-valproic - ecc | HMDB | Novo-valproic soft gel cap | HMDB | Nu-valproic | HMDB | PEAC | HMDB | Penta-valproic | HMDB | PHL-Valproate | HMDB | PHL-Valproic acid | HMDB | PHL-Valproic acid e.c. | HMDB | PMS-Divalproex | HMDB | PMS-Valproate | HMDB | PMS-Valproic acid | HMDB | PMS-Valproic acid e.c. | HMDB | Propylvaleric acid | HMDB | Ratio-valproic - ecc | HMDB | S(-)-4-En-valproate | HMDB | S(-)-4-En-valproic acid | HMDB | S-2-N-Propyl-4-pentenoate | HMDB | S-2-N-Propyl-4-pentenoic acid | HMDB | Sandoz valproic | HMDB | Savicol | HMDB | Sprinkle | HMDB | Valcote | HMDB | Valparin | HMDB | Valproic acid usp | HMDB | Dipropyl acetate | HMDB | Valproate, sodium | HMDB | Calcium, valproate | HMDB | Convulsofin | HMDB | Semisodium valproate | HMDB | Sodium valproate | HMDB | Valproate calcium | HMDB | Valproate, calcium | HMDB | Valproic acid, sodium salt (2:1) | HMDB | Acetate, dipropyl | HMDB | Depakote | HMDB | Divalproex sodium | HMDB | Magnesium valproate | HMDB | Sodium, divalproex | HMDB | Sodium, valproate | HMDB | Vupral | HMDB | 2 Propylpentanoic acid | HMDB | Acid, propylisopropylacetic | HMDB | Acid, valproic | HMDB | Calcium valproate | HMDB | Propylisopropylacetic acid | HMDB | Valproate sodium | HMDB | Valproate, magnesium | HMDB | Valproate, semisodium | HMDB |
|
---|
Chemical Formula | C8H16O2 |
---|
Average Molecular Weight | 144.2114 |
---|
Monoisotopic Molecular Weight | 144.115029756 |
---|
IUPAC Name | 2-propylpentanoic acid |
---|
Traditional Name | valproic acid |
---|
CAS Registry Number | 99-66-1 |
---|
SMILES | CCCC(CCC)C(O)=O |
---|
InChI Identifier | InChI=1S/C8H16O2/c1-3-5-7(6-4-2)8(9)10/h7H,3-6H2,1-2H3,(H,9,10) |
---|
InChI Key | NIJJYAXOARWZEE-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as methyl-branched fatty acids. These are fatty acids with an acyl chain that has a methyl branch. Usually, they are saturated and contain only one or more methyl group. However, branches other than methyl may be present. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Fatty Acyls |
---|
Sub Class | Fatty acids and conjugates |
---|
Direct Parent | Methyl-branched fatty acids |
---|
Alternative Parents | |
---|
Substituents | - Methyl-branched fatty acid
- Monocarboxylic acid or derivatives
- Carboxylic acid
- Carboxylic acid derivative
- Organic oxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organooxygen compound
- Carbonyl group
- Aliphatic acyclic compound
|
---|
Molecular Framework | Aliphatic acyclic compounds |
---|
External Descriptors | |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Liquid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | 222 °C | Not Available | Water Solubility | 2 mg/mL at 20 °C | Not Available | LogP | 2.75 | SANGSTER (1993) |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatized |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Valproic acid GC-MS (Non-derivatized) - 70eV, Positive | splash10-004m-9300000000-e66da5fefd079f7426a4 | 2017-08-28 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valproic acid GC-MS (1 TMS) - 70eV, Positive | splash10-00b9-9100000000-7bb11c5d52ffa09851f8 | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valproic acid GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Valproic acid GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | MS | Mass Spectrum (Electron Ionization) | splash10-0fk9-9300000000-1a0314ea63d5a3c9bba1 | 2014-09-20 | Not Available | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid Quattro_QQQ 10V, N/A-QTOF (Annotated) | splash10-0udi-2900000000-156413e81733a6236c1f | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid Quattro_QQQ 25V, N/A-QTOF (Annotated) | splash10-0f6y-2900000000-a769cafb885b78532cac | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid Quattro_QQQ 40V, N/A-QTOF (Annotated) | splash10-0gbj-7900000000-46a522b9a26459334f5a | 2012-07-24 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negative-QTOF | splash10-0006-0900000000-39a45d4e3201082d9d89 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negative-QTOF | splash10-0002-9000000000-4ddd957d8c8dc2b1de03 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ (API3000, Applied Biosystems) 10V, Negative-QTOF | splash10-0006-0900000000-6ba582ae102c4721034d | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ (API3000, Applied Biosystems) 20V, Negative-QTOF | splash10-0006-0900000000-58d9ba88010f1b370c58 | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ (API3000, Applied Biosystems) 30V, Negative-QTOF | splash10-0006-3900000000-2d1032d7e8ac58235b4f | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ (API3000, Applied Biosystems) 40V, Negative-QTOF | splash10-0a4j-9000000000-0d39870bc4521a42c50a | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ (API3000, Applied Biosystems) 50V, Negative-QTOF | splash10-00di-9000000000-3c4e21b69b8877d6df3e | 2012-08-31 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ , negative-QTOF | splash10-0006-0900000000-39a45d4e3201082d9d89 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ , negative-QTOF | splash10-0002-9000000000-4ddd957d8c8dc2b1de03 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ , negative-QTOF | splash10-0006-0900000000-6ba582ae102c4721034d | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ , negative-QTOF | splash10-0006-0900000000-58d9ba88010f1b370c58 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ , negative-QTOF | splash10-0006-3900000000-2d1032d7e8ac58235b4f | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ , negative-QTOF | splash10-0a4j-9000000000-0d39870bc4521a42c50a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid LC-ESI-QQ , negative-QTOF | splash10-00di-9000000000-3c4e21b69b8877d6df3e | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid Linear Ion Trap , negative-QTOF | splash10-0006-0900000000-5b83f0d6c36f8249285a | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Valproic acid 20V, Negative-QTOF | splash10-0006-0900000000-51a760d50a87d131ad67 | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valproic acid 10V, Positive-QTOF | splash10-0002-3900000000-be0e79e3b65dad2e2d08 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valproic acid 20V, Positive-QTOF | splash10-0005-9500000000-37d8981251a94cfd51e3 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valproic acid 40V, Positive-QTOF | splash10-0006-9000000000-b63be8686bbf9a96b2ba | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valproic acid 10V, Negative-QTOF | splash10-0006-3900000000-25f23d80c7431c074a74 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valproic acid 20V, Negative-QTOF | splash10-0005-9500000000-144b6cc9fea5bae4f269 | 2017-07-26 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Valproic acid 40V, Negative-QTOF | splash10-052e-9100000000-eb5e97329782125f6615 | 2017-07-26 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 1D NMR | 1H NMR Spectrum (1D, 500 MHz, H2O, experimental) | 2012-12-04 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
IR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M-H]-) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+H]+) | 2023-02-03 | FELIX lab | View Spectrum | Predicted IR Spectrum | IR Ion Spectrum (Predicted IRIS Spectrum, Adduct: [M+Na]+) | 2023-02-03 | FELIX lab | View Spectrum |
|
---|
General References | - Nemeroff CB: The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull. 2003;37(4):133-46. [PubMed:15131523 ]
- Bell EC, Willson MC, Wilman AH, Dave S, Silverstone PH: Differential effects of chronic lithium and valproate on brain activation in healthy volunteers. Hum Psychopharmacol. 2005 Aug;20(6):415-24. [PubMed:16106488 ]
- Sztajnkrycer MD: Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol. 2002;40(6):789-801. [PubMed:12475192 ]
- Seyfert S, Bernarding J, Braun J: Volume-selective 1H MR spectroscopy for in vivo detection of valproate in patients with epilepsy. Neuroradiology. 2003 May;45(5):295-9. Epub 2003 Mar 27. [PubMed:12669157 ]
- Eyal S, Lamb JG, Smith-Yockman M, Yagen B, Fibach E, Altschuler Y, White HS, Bialer M: The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol. 2006 Oct;149(3):250-60. Epub 2006 Aug 7. [PubMed:16894351 ]
- Loscher W: Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16(10):669-94. [PubMed:12269861 ]
- Huang YL, Hong HS, Wang ZW, Kuo TT: Fatal sodium valproate-induced hypersensitivity syndrome with lichenoid dermatitis and fulminant hepatitis. J Am Acad Dermatol. 2003 Aug;49(2):316-9. [PubMed:12894087 ]
- Anderson GD, Temkin NR, Chandler WL, Winn HR: Effect of valproate on hemostatic function in patients with traumatic brain injury. Epilepsy Res. 2003 Dec;57(2-3):111-9. [PubMed:15013052 ]
- Ho PC, Abbott FS, Zanger UM, Chang TK: Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J. 2003;3(6):335-42. [PubMed:14597963 ]
- Gerstner T, Bell N, Konig S: Oral valproic acid for epilepsy--long-term experience in therapy and side effects. Expert Opin Pharmacother. 2008 Feb;9(2):285-92. doi: 10.1517/14656566.9.2.285 . [PubMed:18201150 ]
- Russell S: Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr. 2007 Apr;19(2):206-10. [PubMed:17496767 ]
|
---|